A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, Samir K Gupta, John W Mellors, Laura Moran, Lynne Jones, Beverly Alston-Smith, James F Rooney, Judith A Aberg, Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, Samir K Gupta, John W Mellors, Laura Moran, Lynne Jones, Beverly Alston-Smith, James F Rooney, Judith A Aberg
Abstract
Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.
Conflict of interest statement
Conflict of Interest Notification: Original signed copy will be mailed.
MT: no conflicts
DWK: no conflicts
MJG: no conflicts
SKG: Gilead Sciences: Speaker’s fees, consultant fees, and grant support
JWM: Gilead Sciences: Consultant
Merck: Consultant and grant support
Chimerix: Consultant
RFS Pharmaceuticals: Owns stock options
LM: no conflicts
LJ: no conflicts
BAS: no conflicts
JFR: employee of Gilead Sciences
JAA: Gilead Sciences: Advisory Board, Clinical Trial support, CME sponsored events Honorarium
Source: PubMed